Ralmitaront

Ralmitaront
Clinical data
Other names	RG-7906; RG7906; RO-6889450; RO6889450
Identifiers
	IUPAC name 5-Ethyl-4-methyl-N-[4-[(2S)-morpholin-2-yl]phenyl]-1H-pyrazole-3-carboxamide;
CAS Number	2133417-13-5;
PubChem CID	130429734;
ChemSpider	88298290;
UNII	QA8MW1Q80P;
KEGG	D11830;
ChEMBL	ChEMBL4594376;
CompTox Dashboard (EPA)	DTXSID901336976 ;
Chemical and physical data
Formula	C17H22N4O2
Molar mass	314.389 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCC1=C(C(=NN1)C(=O)NC2=CC=C(C=C2)[C@H]3CNCCO3)C;
	InChI InChI=1S/C17H22N4O2/c1-3-14-11(2)16(21-20-14)17(22)19-13-6-4-12(5-7-13)15-10-18-8-9-23-15/h4-7,15,18H,3,8-10H2,1-2H3,(H,19,22)(H,20,21)/t15-/m1/s1; Key:XHHXGKRFUPEPFM-OAHLLOKOSA-N;

Ralmitaront (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names RG-7906 and RO-6889450) is an investigational antipsychotic drug which was undergoing a Phase II clinical trial for the treatment of negative symptoms in schizophrenia and schizoaffective disorder, but the trial was discontinued due to lack of efficacy.^[1]^[2]^[3]^[4] Another Phase II clinical trial targeting acute psychotic symptoms of schizophrenia was also terminated for the same reason.^[5] It is a partial agonist of the TAAR1 protein.^[6] The medication is being developed by the pharmaceutical company Hoffmann-La Roche.^[1] Ralmitaront had completed Phase I clinical trials.^[1]^[7]